Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On September 16, 2025, Dr. Reddy’s Laboratories announced the launch of Tegoprazan, a novel potassium-competitive acid blocker, in India under the brand name PCAB®. This launch follows their 2022 partnership with South Korea’s HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets. Tegoprazan is designed to treat acid-related gastrointestinal diseases such as GERD and gastric ulcers, offering a fast onset of action and prolonged gastric pH control. With acid peptic diseases affecting approximately 38% of the Indian population, this launch aims to fill a critical gap in treatment options, potentially improving patient outcomes. Tegoprazan has already been approved in 21 countries and is undergoing registration in several others, including successful completion of a Phase-III trial in the United States.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company focuses on providing affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Their major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with significant markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe.
Average Trading Volume: 1,237,160
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.31B
See more data about RDY stock on TipRanks’ Stock Analysis page.